Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease
- PMID: 15922812
- DOI: 10.1016/j.clinthera.2005.04.006
Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease
Abstract
Background: Tiotropium bromide is a new inhaled anticholinergic agent approved for once-daily, long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Objective: This article reviews the pharmacology, pharmacokinetic and pharmacodynamic properties, clinical efficacy, tolerability, and cost of tiotropium therapy in patients with COPD.
Methods: The MEDLINE (1966-October 2004), Iowa Drug Information Service (1966-October 2004), and International Pharmaceutical Abstracts (1970-November 2004) databases were searched for original research and review articles published in English. The search terms were tiotropium, Ba 679 BR, and HandiHaler. Reference lists from these articles were also consulted, as was selected information provided by the manufacturer of tiotropium. All relevant identified studies were included in the review, with preference given to Phase II/III trials. Pharmacoeconomic studies were limited to those conducted in the United States.
Results: Tiotropium is a nonselective anticholinergic agent that exhibits kinetic receptor selectivity for the muscarinic M1 and M3 receptors. After inhalation, tiotropium has an onset of action within 30 minutes, a peak effect within 3 to 4 hours, and a > or = 24-hour duration of action that allows once-daily dosing. In clinical trials, patients receiving tiotropium 18 microg QD had significant improvements in trough, peak, and mean forced expiratory volume in 1 second (FEV1), dyspnea, and health-related quality of life, as well as fewer COPD exacerbations and hospitalizations, compared with patients receiving placebo and ipratropium (all, P < 0.05). Improvement in FEV1 was also significantly greater in patients who received tiotropium compared with those who received salmeterol (P < 0.05), although the number of exacerbations and extent of health resource use were comparable between groups. Dry mouth was the most commonly reported adverse effect. One analysis found tiotropium to be cost-effective compared with ipratropium.
Conclusions: Tiotropium offers several advantages over ipratropium in the management of COPD. Long-term (> 1 year) studies are necessary to determine the impact of tiotropium on disease progression and life expectancy.
Similar articles
-
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005. Treat Respir Med. 2004. PMID: 15350163 Review.
-
Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.Ann Pharmacother. 2005 Sep;39(9):1467-75. doi: 10.1345/aph.1E469. Epub 2005 Jul 19. Ann Pharmacother. 2005. PMID: 16030078 Review.
-
[Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)].Pneumologie. 2003 Sep;57(9):519-25. doi: 10.1055/s-2003-42216. Pneumologie. 2003. PMID: 13680472 Review. German.
-
Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Ann Pharmacother. 2008 Dec;42(12):1832-42. doi: 10.1345/aph.1L250. Epub 2008 Oct 28. Ann Pharmacother. 2008. PMID: 18957624 Review.
-
[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].Pneumologie. 2006 Jun;60(6):341-6. doi: 10.1055/s-2005-919145. Pneumologie. 2006. PMID: 16761228 Clinical Trial. German.
Cited by
-
Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Drugs Aging. 2014 Jan;31(1):55-65. doi: 10.1007/s40266-013-0141-5. Drugs Aging. 2014. PMID: 24293180
-
V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results.Respir Res. 2015 Jun 8;16(1):68. doi: 10.1186/s12931-015-0227-1. Respir Res. 2015. PMID: 26050967 Free PMC article. Clinical Trial.
-
Plant derived substances with anti-cancer activity: from folklore to practice.Front Plant Sci. 2015 Oct 1;6:799. doi: 10.3389/fpls.2015.00799. eCollection 2015. Front Plant Sci. 2015. PMID: 26483815 Free PMC article. Review.
-
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma.Allergy Asthma Immunol Res. 2017 Sep;9(5):386-393. doi: 10.4168/aair.2017.9.5.386. Allergy Asthma Immunol Res. 2017. PMID: 28677351 Free PMC article. Review.
-
Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation.Transl Clin Pharmacol. 2017 Jun;25(2):85-92. doi: 10.12793/tcp.2017.25.2.85. Epub 2017 Jun 15. Transl Clin Pharmacol. 2017. PMID: 32133324 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical